Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaLymphadenopathyMetastatic Prostate CarcinomaProstate AdenocarcinomaProstate Small Cell CarcinomaProstate Carcinoma Metastatic in the Bone
- Interventions
- First Posted Date
- 2012-01-09
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 170
- Registration Number
- NCT01505868
- Locations
- πΊπΈ
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
πΊπΈM D Anderson Cancer Center, Houston, Texas, United States
Reducing Cancer Disparities Among Latinos in Texas
Not Applicable
Completed
- Conditions
- Psychosocial Problem
- Interventions
- Behavioral: Health EducationBehavioral: QuestionnairesBehavioral: Telephone Counseling Sessions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 301
- Registration Number
- NCT01504919
- Locations
- πΊπΈ
William Marsh Rice University, Houston, Texas, United States
πΊπΈUniversity of Texas MD Anderson Cancer Center, Houston, Texas, United States
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Early Phase 1
Completed
- Conditions
- Fallopian Tube Undifferentiated CarcinomaStage IIC Fallopian Tube Cancer AJCC v6 and v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Ovarian Clear Cell AdenocarcinomaStage II Fallopian Tube Cancer AJCC v6 and v7Stage IIA Ovarian Cancer AJCC V6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIC Fallopian Tube Cancer AJCC v7
- Interventions
- Drug: ChemotherapyOther: Quality-of-Life AssessmentProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT01504126
- Locations
- πΊπΈ
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
πΊπΈM D Anderson Cancer Center, Houston, Texas, United States
πΊπΈMD Anderson in Katy, Houston, Texas, United States
Part II: Exercise in Hispanic Breast Cancer Survivors
Not Applicable
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Behavioral: Baseline Fitness TestBehavioral: QuestionnairesBehavioral: Individualized Exercise ProgramBehavioral: Written Materials
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT01504789
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
π΅π·University of Puerto Rico, San Juan, Puerto Rico
Data Collection of Normal Tissue Toxicity for Proton Therapy for Pediatrics
- Conditions
- Pediatric Cancer
- Interventions
- Other: Data CollectionOther: Dose Distribution Data Collection
- First Posted Date
- 2011-12-30
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 798
- Registration Number
- NCT01502150
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Respiratory Syncytial Virus - RSV Protocol
Phase 2
Completed
- Conditions
- Acute LeukemiaInfection in Marrow Transplant RecipientsRespiratory Syncytial Virus InfectionsBone Marrow Transplant InfectionRespiratory Syncytial Virus PneumoniaCancer
- Interventions
- First Posted Date
- 2011-12-30
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT01502072
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT01498445
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
Phase 1
Completed
- Conditions
- LeukemiaLymphoma
- Interventions
- Procedure: HSCTGenetic: DLI
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 95
- Registration Number
- NCT01497184
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Long-Term Follow-Up of Recipient of Gene Transfer Research
Recruiting
- Conditions
- Retroviridae InfectionsCancer
- Interventions
- Other: Blood TestsBehavioral: Questionnaires
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 130
- Registration Number
- NCT01492036
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
R-21 Colorectal Cancer Screening (CRCS) Pilot Trial
Not Applicable
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- Behavioral: CRCS patient decision aid (PtDA) videoBehavioral: QuestionnairesBehavioral: Essential Hypertension video
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 107
- Registration Number
- NCT01492049
- Locations
- πΊπΈ
Harris County Hospital District, Houston, Texas, United States